Trending Articles

article thumbnail

Clash Of Drugs Impedes Lung Cancer Treatment, Lowers Survival

Drugs.com

TUESDAY, July 7, 2025 — Two drugs used in lung cancer treatment appear to be tripping over each other, reducing patients’ chances for a cure, a new study says.Corticosteroids are commonly prescribed to alleviate cancer-related symptoms in patients w.

Treatment 258
article thumbnail

Lilly gets FDA OK of modified dosing for Alzheimer’s drug

BioPharma Drive: Drug Pricing

A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to prescribe Lilly’s amyloid-busting drug.

Doctors 191
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Scientists reverse Parkinson’s symptoms in mice — Could humans be next?

Science Daily: Pharmacology News

Scientists at the University of Sydney have uncovered a malfunctioning version of the SOD1 protein that clumps inside brain cells and fuels Parkinson’s disease. In mouse models, restoring the protein’s function with a targeted copper supplement dramatically rescued movement, hinting at a future therapy that could slow or halt the disease in people.

Therapies 240
article thumbnail

Collaborative Drug Discovery and deepmirror Announce Collaboration for Humanitarian and Commercial Drug Discovery

Collaborative Drug

BURLINGAME, Calif. — July 8, 2025. Collaborative Drug Discovery (CDD) , the leading provider of data management solutions for the pharmaceutical and biotechnology industries, and deepmirror , the AI drug design platform that empowers chemists to focus on more promising drug molecules, today announced a strategic partnership integrating deepmirror with CDD Vault to enhance drug discovery.

Drugs 147
article thumbnail

Bridging Innovation & Patient Care: The Growing Role of AI

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

article thumbnail

Rational Design of CDK12/13 and BRD4 Molecular Glue Degraders

Covalent Modifiers

Nathanael Schiander Gray , Zhe Zhuang , Woong Sub Byun , Zuzanna Kozicka , Katherine Donovan , Brendan Dwyer , Abby Thornhill , Hannah Jones , Zixuan Jiang , Xijun Zhu , Eric Fischer , Nicolas Thomä , Angew. Chem. Int. Ed. 2025 , e202508427. [link] Targeted protein degradation (TPD) is an emerging therapeutic approach for the selective elimination of disease-related proteins.

article thumbnail

Cough medicine turned brain protector? Ambroxol may slow Parkinson’s dementia

Science Daily: Pharmacology News

Ambroxol, long used for coughs in Europe, stabilized symptoms and brain-damage markers in Parkinson’s dementia patients over 12 months, whereas placebo patients worsened. Those with high-risk genes even saw cognitive gains, hinting at real disease-modifying power.

Disease 216

More Trending

article thumbnail

After delay, Kalvista wins FDA OK for drug to treat rare swelling disorder

BioPharma Drive: Drug Pricing

The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an on-time approval.

FDA 241
article thumbnail

Computationally Guided Structural Modification of Centaureidin: A Novel Approach for Enhancing Antioxidant and Antitumor Activities for Drug Development

Chemical Biology and Drug Design

Computationally guided modifications of centaureidin led to the development of CA4, demonstrating enhanced antioxidant and antitumor activities. Molecular docking and in vitro assays confirm improved binding affinity and cytotoxicity, highlighting CA4's potential as a promising drug candidate for cancer therapy. ABSTRACT The development of novel therapeutic drugs with enhanced efficacy has gained significant attention in recent years.

article thumbnail

Future-proofing drug development with GenAI

Drug Target Review

It is becoming increasingly evident that generative artificial intelligence (GenAI) is a resourceful tool for helping pharmaceutical companies reduce manual tasks required by clinical trials. However, R&D stakeholders are learning that GenAI underpinned by domain expertise also enables deep dives into the broader long-term potential of their investigational asset(s) as early as the preclinical phase.

article thumbnail

A cholesterol secret inside ticks may halt Lyme disease spread

Science Daily: Pharmacology News

Scientists have discovered that the bacteria behind Lyme disease and anaplasmosis have a sneaky way of surviving inside ticks—they hijack the tick’s own cell functions to steal cholesterol they need to grow. By tapping into a built-in protein pathway, the bacteria keep themselves alive until they can infect a new host. The research opens the door to new methods of stopping these diseases before ticks ever get the chance to bite.

Disease 201
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

First Malaria Drug Approved for Newborns and Small Babies, Coartem Baby

Drugs.com

WEDNESDAY, July 9, 2025 — A new malaria treatment has been approved for newborns and infants under 11 pounds, filling a major gap in care for some of the most vulnerable children. The medicine, called Coartem Baby (also known as Riamet Baby).

Treatment 269
article thumbnail

Novartis gets approval of first malaria medicine for newborns

BioPharma Drive: Drug Pricing

Coartem Baby, which was cleared by health authorities in Switzerland, will fill an important gap in treatment. Novartis plans to sell it “largely” on a not-for-profit basis.

Treatment 191
article thumbnail

Assembling data sets for training ML bioactivity models

Molecular Design

Here’s a photo from one of my exercise walks in Paramin and you can see the Caribbean Sea in the distance. This is perhaps my favourite view on the walk because it means that I’ve just got to the top of a particularly brutal hill (cars sometimes struggle to get to the top and on one occasion I watched a car fail miserably in four attempts) although you can’t always see the sea as clearly as in this photo.

article thumbnail

Tips and Tricks for Using Golden Gate Modular Cloning (MoClo)

addgene Blog

This post was written by Alfonso Timoneda, with significant contributions from Robert Hurt and Mohamed Soufi. So you’ve learned about the Modular Cloning (MoClo) system and what it can do for you, and you’ve chosen one of the MoClo kits available through Addgene that suits your experimental purposes. But what now? MoClo really simplifies vector construction by combining restriction and ligation steps together in the same tube at the same time, however, it can prove itself to be quite the mental

76
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Your Brain’s Hidden Defenses Against Alzheimer’s

Science Daily: Pharmacology News

Scientists at UCSF combined advanced brain-network modeling, genetics, and imaging to reveal how tau protein travels through neural highways and how certain genes either accelerate its toxic journey or shield brain regions from damage. Their extended Network Diffusion Model pinpoints four gene categories that govern vulnerability or resilience, reshaping our view of Alzheimer’s progression and spotlighting fresh therapeutic targets.

140
140
article thumbnail

Type Of Hormone Therapy Can Alter Breast Cancer Risk, Study Says

Drugs.com

MONDAY, July 7, 2025 — Some women have expressed concerns about the risk of breast cancer associated with using hormone therapy to treat symptoms of menopause like hot flashes and night sweats, and now, new research suggests that one type of.

Therapies 260
article thumbnail

Actithera draws new investors to radiopharma drug pitch

BioPharma Drive: Drug Pricing

Skip to main content CONTINUE TO SITE ➞ Dont miss tomorrows biopharma industry news Let BioPharma Dives free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy.

Drugs 140
article thumbnail

Generative AI Can Design Drugs. But Can It Own Them?

Drug Patent Watch

"The Future of Pharma is in Flux: Can AI-Designed Medicines Be Owned? As the pharmaceutical industry grapples with the rise of generative AI, a new question is emerging: who owns the rights to medicines designed by machines? In a groundbreaking development, researchers have successfully used AI to design novel compounds with unprecedented efficacy.

article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

PALAZESTRANT

New Drug Approvals

PALAZESTRANT CAS 2092925-89-6 OP-1250, VU35KM56Q4 449.6 g/mol, C 28 H 36 FN 3 O (1 R ,3 R )-2-(2-fluoro-2-methylpropyl)-3-methyl-1-[4-(1-propylazetidin-3-yl)oxyphenyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole (1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-1-[4-(1-propylazetidin-3-yl)oxyphenyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole (1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-1-{4-[(1-propylazetidin-3- yl)oxy]phenyl}-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole Palazestrant (OP-1250) is an investigationa

article thumbnail

New tech tracks blood sodium without a single needle

Science Daily: Pharmacology News

Scientists have pioneered a new way to monitor sodium levels in the blood—without drawing a single drop. By combining terahertz radiation and optoacoustic detection, they created a non-invasive system that tracks sodium in real time, even through skin. The approach bypasses traditional barriers like water interference and opens up potential for fast, safe diagnostics in humans.

178
178
article thumbnail

Three-Quarters of Stomach Cancers Could Be Prevented By Targeting Helicobacter Pylori Bacteria

Drugs.com

TUESDAY, July 8, 2025 — Three-quarters of stomach cancer cases could be prevented if doctors eradicate infection by a common type of bacteria, a new study says. The bacteria, Helicobacter pylori, is linked to 76% of future stomach cancer.

Doctors 222
article thumbnail

Cargo agrees to Concentra buyout after trial setback, layoffs

BioPharma Drive: Drug Pricing

The cell therapy developer, which raised nearly $500 million in 2023 on the promise of its CAR-T work, has floundered since a safety setback forced it to scrap its lead candidate.

Trials 162
article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

Best Practices for Pitching, Geared Towards First-Time Founders

LifeSciVC

By Aimee Raleigh, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC If you are a first-time founder who has heard the phrase “This isn’t a good time to be raising for X,” where X is a platform, a preclinical play, a non-consensus story, I empathize! After you’ve spent years contemplating an idea, potentially investing some of your own money to generate early data, and carefully thinking through the pitch, it’s difficult to hear that an entire scope of companies is

76
article thumbnail

Sunvozertinib

New Drug Approvals

Sunvozertinib CAS 2370013-12-8 DZD9008, 584.1 g/mol, C 29 H 35 ClFN 7 O 3 , A-1801, L1Q2K5JYO8 N -[5-[[4-[5-chloro-4-fluoro-2-(2-hydroxypropan-2-yl)anilino]pyrimidin-2-yl]amino]-2-[(3 R )-3-(dimethylamino)pyrrolidin-1-yl]-4-methoxyphenyl]prop-2-enamide FDA Zegfrovy, 7/2/2025 To treat locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations, as detected by an FDA-approved test, with disease progression on or after platinum-based c

FDA 62
article thumbnail

Breakthrough battery lets physicists reverse entanglement—and rewrite quantum law

Science Daily: Pharmacology News

Scientists have finally uncovered a quantum counterpart to Carnot’s famed second law, showing that entanglement—once thought stubbornly irreversible—can be shuffled back and forth without loss if you plug in a clever “entanglement battery.

266
266
article thumbnail

Barbie's Latest Look? It Includes an Insulin Pump and Glucose Monitor

Drugs.com

WEDNESDAY, July 9, 2025 — Barbie’s latest look includes a polka-dot crop top, chunky heels — and an insulin pump.Mattel has released its first-ever Barbie with type 1 diabetes, complete with a glucose monitor, phone app and a purse packed with suppl.

260
260
article thumbnail

Apogee touts positive data for atopic dermatitis drug

BioPharma Drive: Drug Pricing

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less frequent dosing.

Treatment 147
article thumbnail

AI and Digital Trends Marketing and IT Leaders Need to Know

Perficient: Drug Development

In Adobe’s 2025 AI and Digital Trends report, one message rings loud and clear: the convergence of marketing and IT is essential to digital success. As AI becomes increasingly embedded in customer experience strategies, marketing and IT leaders must collaborate closely to unlock its full potential. The Rise of Agentic AI One of the most transformative ideas in the report is the rise of agentic AI, autonomous systems that collaborate across platforms to deliver hyper-personalized, real-time exper

article thumbnail

Leadership in the Age of Stacks

LifeSciVC

By Jason Campagna, CMO of Q32, as part of the From The Trenches feature of LifeSciVC In a recent essay, I argued that biotech is entering its strategic infrastructure moment, a shift from molecule-centric innovation to a layered capability stack beneath the therapeutic. The core claim was structural: the future of biotech depends as much on what supports the drug as what is in it.

article thumbnail

Honey bees remove 80% of pollen—leaving native bees with nothing

Science Daily: Pharmacology News

Feral honey bees, once celebrated for their agricultural value, are now threatening native ecosystems in Southern California by monopolizing pollen sources and overwhelming native pollinators. A new study reveals they remove up to 80% of pollen in a single day, severely disrupting food sources for over 700 species of native bees. Despite their benefits to agriculture, these invasive bees dominate nearly all bee biomass in the region and even produce lower-quality offspring when pollinating nativ

197
197
article thumbnail

Insured? You're More Likely To Survive Cancer Through Immunotherapy Treatment

Drugs.com

WEDNESDAY, July 9, 2025 — Powerful new immunotherapies are offering fresh hope for patients with many different types of cancer.Unfortunately, that hope doesn’t extend to people without health insurance, a new study says.Immune checkpoint inh.

Treatment 147
article thumbnail

Study results boost Cogent’s case for rare disease drug

BioPharma Drive: Drug Pricing

One analyst described Cogent’s data as a “home run scenario” for bezuclastinib, which the company is positioning as a competitor to Blueprint Medicines’ Ayvakit.

Disease 147